Molecular Partners AG (MLLCF)
USD 4.22
(0.24%)
USD 4.22
(0.24%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -183.23 Million CHF | -120.51% |
| 2022 | -83.09 Million CHF | -26.34% |
| 2021 | -65.77 Million CHF | 48.01% |
| 2020 | -126.5 Million CHF | -72.9% |
| 2019 | -73.16 Million CHF | 26.06% |
| 2018 | -98.95 Million CHF | 24.64% |
| 2017 | -131.31 Million CHF | 12.3% |
| 2016 | -149.73 Million CHF | 23.36% |
| 2015 | -195.36 Million CHF | -3.71% |
| 2014 | -188.38 Million CHF | -95.97% |
| 2013 | -96.12 Million CHF | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -170.78 Million CHF | 6.8% |
| 2024 Q2 | -156.07 Million CHF | 63.32% |
| 2023 Q3 | -64.44 Million CHF | -9.25% |
| 2023 Q1 | -69.37 Million CHF | 16.51% |
| 2023 Q2 | -58.99 Million CHF | 14.97% |
| 2023 FY | -183.23 Million CHF | -120.51% |
| 2023 Q4 | -183.23 Million CHF | -184.32% |
| 2022 Q1 | -136.27 Million CHF | -107.19% |
| 2022 Q3 | -64.55 Million CHF | 41.04% |
| 2022 Q4 | -83.09 Million CHF | -28.72% |
| 2022 FY | -83.09 Million CHF | -26.34% |
| 2022 Q2 | -109.49 Million CHF | 19.65% |
| 2021 Q2 | -119.93 Million CHF | 13.51% |
| 2021 Q4 | -65.77 Million CHF | 14.1% |
| 2021 FY | -65.77 Million CHF | 48.01% |
| 2021 Q1 | -138.67 Million CHF | -9.63% |
| 2021 Q3 | -76.57 Million CHF | 36.16% |
| 2020 Q4 | -126.5 Million CHF | 0.0% |
| 2020 FY | -126.5 Million CHF | -72.9% |
| 2020 Q2 | -45.4 Million CHF | -147.75% |
| 2020 Q1 | 95.08 Million CHF | 229.95% |
| 2019 FY | -73.16 Million CHF | 26.06% |
| 2019 Q3 | -74.43 Million CHF | -15.46% |
| 2019 Q1 | -65.72 Million CHF | 33.59% |
| 2019 Q2 | -64.46 Million CHF | 1.91% |
| 2019 Q4 | -73.16 Million CHF | 1.7% |
| 2018 FY | -98.95 Million CHF | 24.64% |
| 2018 Q1 | -92.66 Million CHF | 29.43% |
| 2018 Q4 | -98.95 Million CHF | 0.0% |
| 2018 Q3 | -98.95 Million CHF | -6.79% |
| 2018 Q2 | -92.66 Million CHF | 0.0% |
| 2017 Q3 | -131.31 Million CHF | -10.76% |
| 2017 Q4 | -131.31 Million CHF | 0.0% |
| 2017 FY | -131.31 Million CHF | 12.3% |
| 2017 Q1 | 180.22 Million CHF | 220.36% |
| 2017 Q2 | -118.55 Million CHF | -165.78% |
| 2016 Q1 | 215.39 Million CHF | 210.25% |
| 2016 Q2 | -176.78 Million CHF | -182.07% |
| 2016 Q4 | -149.73 Million CHF | -176.26% |
| 2016 FY | -149.73 Million CHF | 23.36% |
| 2016 Q3 | 196.34 Million CHF | 211.07% |
| 2015 FY | -195.36 Million CHF | -3.71% |
| 2015 Q1 | 188.38 Million CHF | 200.0% |
| 2015 Q4 | -195.36 Million CHF | 0.0% |
| 2015 Q2 | -175.63 Million CHF | -193.23% |
| 2014 Q1 | 96.12 Million CHF | 0.0% |
| 2014 FY | -188.38 Million CHF | -95.97% |
| 2014 Q4 | -188.38 Million CHF | 0.0% |
| 2013 FY | -96.12 Million CHF | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -27123.294% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 15195.05% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 18283.397% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 528.194% |
| GB Sciences, Inc. | 1.74 Million USD | 10586.769% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -1972.837% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -1976920.696% |
| Skye Bioscience, Inc. | -5.72 Million USD | -3102.666% |
| Zenith Capital Corp. | 10.06 Thousand USD | 1820817.409% |
| Agentix Corp. | 37.63 Thousand USD | 487030.988% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 3344.069% |
| Biomind Labs Inc. | 711.4 Thousand USD | 25857.167% |
| ContraFect Corporation | -6.02 Million USD | -2940.773% |
| CSL Limited | 10.52 Billion USD | 101.741% |
| CytoDyn Inc. | 20.26 Million USD | 1004.338% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 51040.202% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 29542.095% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 521.875% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -897768.483% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 19862.701% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 28948.634% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -2806.437% |
| SQZ Biotechnologies Company | -36.23 Million USD | -405.649% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 21400.659% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 1262.45% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 8272.077% |
| Mesoblast Limited | 55.85 Million USD | 428.039% |
| Marizyme, Inc. | 18.56 Million USD | 1086.788% |
| Genus plc | 190.6 Million USD | 196.137% |
| Pharming Group N.V. | 109.8 Million USD | 266.876% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 27046.618% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 15958.785% |
| IMV Inc. | 7.67 Million USD | 2488.847% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 3430.434% |
| MultiCell Technologies, Inc. | 90.04 USD | 203506319.458% |
| ONE Bio Corp. | 9.04 Million USD | 2126.95% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 1515.395% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 699.715% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 9264.636% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 1530.802% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 131167.065% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 922418.417% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -99600.198% |
| Enzolytics Inc. | 981.65 Thousand USD | 18766.111% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 90.968% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -289.766% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 2691.398% |
| Genscript Biotech Corporation | -1.06 Billion USD | 82.735% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 4549.634% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 45698.471% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 7779.564% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 111484.18% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -1000211.169% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 8295.473% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 136195.039% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -24864.917% |
| Helix BioMedix, Inc. | -2.57 Million USD | -7029.756% |
| EV Biologics, Inc. | 1.36 Million USD | 13494.801% |
| Q BioMed Inc. | 4.06 Million USD | 4613.218% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 1003.714% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 402.642% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 4197.418% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 8421.461% |
| HST Global, Inc. | 96.79 Thousand USD | 189408.111% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -13987457.252% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 88956.399% |
| Halberd Corporation | 144.72 Thousand USD | 126713.968% |
| Resverlogix Corp. | 6.45 Million USD | 2940.443% |
| Cell Source, Inc. | 9.23 Million USD | 2084.809% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 6864.97% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -5.9 Million USD | -3004.025% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 91521.031% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | 8511.29% |
| Kadimastem Ltd | -253.1 Thousand USD | -72296.504% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 134843.987% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 91147.631% |
| LadRx Corporation | -2.03 Million USD | -8897.78% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 28948.634% |
| Affymax, Inc. | -5.59 Million USD | -3173.843% |
| Itoco Inc. | 228.3 Thousand USD | 80359.74% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 3796.53% |
| Mobile Lads Corp. | 484.23 Thousand USD | 37940.746% |
| International Stem Cell Corporation | 2.59 Million USD | 7174.788% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | 1.89 Million USD | 9749.568% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -28320920.093% |
| Qrons Inc. | 351.42 Thousand USD | 52240.843% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 2477.848% |
| SYBLEU INC | 473.71 Thousand USD | 38780.934% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -73306.378% |
| Rebus Holdings, Inc. | 305 Thousand USD | 60177.705% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 4211.198% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 293687.874% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 8501.898% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 5435.964% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 2242.371% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 23816.715% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -14558.96% |
| Neutra Corp. | 52.18 Thousand USD | 351216.178% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -7261.872% |
| PureTech Health plc | -167.19 Million USD | -9.593% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -74718.707% |
| IXICO plc | -4.44 Million USD | -4022.7% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 1486.164% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 434.063% |
| CSL Limited | 10.52 Billion USD | 101.741% |
| Cellectis S.A. | -43.81 Million USD | -318.169% |